Role of CXCL9/CXCR3 Chemokine Biology during Pathogenesis of Acute Lung Allograft Rejection 1

Acute allograft rejection is a major complication postlung transplantation and is the main risk factor for the development of bronchiolitis obliterans syndrome. Acute rejection is characterized by intragraft infiltration of activated mononuclear cells. The ELR-negative CXC chemokines CXCL9, CXCL10, and CXCL11) are potent chemoattractants for mononuclear cells and act through their shared receptor, CXCR3. Elevated levels of these chemokines in bronchoalveolar lavage fluid have been associated with human acute lung allograft rejection. This led to the hypothesis that the expression of these chemokines during an allogeneic response promotes the recruitment of mononuclear cells, leading to acute lung allograft rejection. We performed studies in a rat orthotopic lung transplantation model of acute rejection, and demonstrated increased expression of CXCL9 and CXCL10 paralleling the recruitment of mononuclear cells and cells expressing CXCR3 to the allograft. However, CXCL9 levels were 15-fold greater than CXCL10 during maximal rejection. Inhibition of CXCL9 decreased intragraft recruitment of mononuclear cells and cellular expression of CXCR3, resulting in lower acute lung allograft rejection scores. Furthermore, the combination of low dose cyclosporin A with anti-CXCL9 therapy had more profound effects on intragraft leukocyte infiltration and in reducing acute allograft rejection scores. This supports the notion that CXCL9 interaction with cells expressing CXCR3 has an important role in the recruitment of mononuclear cells, a pivotal event in the pathogenesis of acute lung allograft rejection.

[1]  H. Date,et al.  [Lung transplantation]. , 2005, Nihon rinsho. Japanese journal of clinical medicine.

[2]  J. Squifflet,et al.  A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients1 , 2003, Transplantation.

[3]  R. Colvin,et al.  Further Analysis of the T‐Cell Subsets and Pathways of Murine Cardiac Allograft Rejection , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  三浦 正義 Monokine induced by IFN-γ is a dominant factor directing T cells into murine cardiac allografts during acute rejection , 2003 .

[5]  M. Burdick,et al.  Critical role for CXCR2 and CXCR2 ligands during the pathogenesis of ventilator-induced lung injury. , 2002, The Journal of clinical investigation.

[6]  M. Fishbein,et al.  The role of MIG/CXCL9 in cardiac allograft vasculopathy. , 2002, The American journal of pathology.

[7]  M. Burdick,et al.  Critical Role for CXCR3 Chemokine Biology in the Pathogenesis of Bronchiolitis Obliterans Syndrome1 , 2002, The Journal of Immunology.

[8]  M. Burdick,et al.  Interleukin-1 receptor antagonist as a biomarker for bronchiolitis obliterans syndrome in lung transplant recipients. , 2002, Transplantation.

[9]  Z. Aalamian Reducing adverse effects of immunosuppressive agents in kidney transplant recipients. , 2001, Progress in transplantation.

[10]  M. Kasper,et al.  Anti-proliferative properties of the phosphodiesterase-4 inhibitor rolipram can supplement immunosuppressive effects of cyclosporine for treatment of obliterative bronchiolitis in heterotopic rat allografts. , 2001, The Journal of Heart and Lung Transplantation.

[11]  I. S. Dunn,et al.  Tracking membrane and secretory immunoglobulin α heavy chain mRNA variation during B‐cell differentiation by real‐time quantitative polymerase chain reaction , 2001, Immunology and cell biology.

[12]  J. Squifflet,et al.  INDUCTION VERSUS NONINDUCTION IN RENAL TRANSPLANT RECIPIENTS WITH TACROLIMUS-BASED IMMUNOSUPPRESSION1 , 2001, Transplantation.

[13]  M. Burdick,et al.  Monokine Induced by IFN-γ Is a Dominant Factor Directing T Cells into Murine Cardiac Allografts During Acute Rejection1 , 2001, The Journal of Immunology.

[14]  D. Remick,et al.  Early Chemokine Cascades in Murine Cardiac Grafts Regulate T Cell Recruitment and Progression of Acute Allograft Rejection1 , 2001, The Journal of Immunology.

[15]  F. Rea,et al.  Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. , 2001, The American journal of pathology.

[16]  H. Reichenspurner,et al.  Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[17]  T. Strom,et al.  ADJUNCTIVE RAPAMYCIN AND CsA TREATMENT INHIBITS MONOCYTE/MACROPHAGE ASSOCIATED CYTOKINES/CHEMOKINES IN SENSITIZED CARDIAC GRAFT RECIPIENTS1 , 2001, Transplantation.

[18]  A. Luster,et al.  Donor-Derived Ip-10 Initiates Development of Acute Allograft Rejection , 2001, The Journal of experimental medicine.

[19]  C. Weber,et al.  A Non-peptide Functional Antagonist of the CCR1 Chemokine Receptor Is Effective in Rat Heart Transplant Rejection* , 2001, The Journal of Biological Chemistry.

[20]  W. Hancock,et al.  Requirement of the Chemokine Receptor CXCR3 for Acute Allograft Rejection , 2000, The Journal of experimental medicine.

[21]  R. Gill,et al.  CD4 T cell-mediated cardiac allograft rejection requires donor but not host MHC class II. , 2000, The Journal of clinical investigation.

[22]  M. Burdick,et al.  The Role of the CC Chemokine, RANTES, in Acute Lung Allograft Rejection1 , 2000, The Journal of Immunology.

[23]  C. Tannenbaum,et al.  Intraallograft Chemokine RNA and Protein During Rejection of MHC-Matched/Multiple Minor Histocompatibility-Disparate Skin Grafts1 , 2000, The Journal of Immunology.

[24]  H. Sarau,et al.  Identification and molecular characterization of rat CXCR3: receptor expression and interferon-inducible protein-10 binding are increased in focal stroke. , 2000, Molecular pharmacology.

[25]  G. Berry,et al.  Successful treatment of acute, ongoing rat lung allograft rejection with the novel immunosuppressant SDZ-RAD. , 2000, The Annals of thoracic surgery.

[26]  A. Novick,et al.  T cell infiltration into class II MHC-disparate allografts and acute rejection is dependent on the IFN-gamma-induced chemokine Mig. , 1999, Journal of immunology.

[27]  J. Gaynor,et al.  Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. , 1999, Chest.

[28]  M. Burdick,et al.  Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. , 1999, Journal of immunology.

[29]  R. Rabin,et al.  Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling. , 1999, Journal of immunology.

[30]  A. J. Chandrasekhar,et al.  Analysis of risk factors for the development of bronchiolitis obliterans syndrome. , 1999, American journal of respiratory and critical care medicine.

[31]  James G. Boyd,et al.  Interferon–inducible T Cell Alpha Chemoattractant (I-TAC): A Novel Non-ELR CXC Chemokine with Potent Activity on Activated T Cells through Selective High Affinity Binding to CXCR3 , 1998, The Journal of experimental medicine.

[32]  Arthur S Slutsky,et al.  Adenovirus-mediated interleukin-10 gene transfer inhibits post-transplant fibrous airway obliteration in an animal model of bronchiolitis obliterans. , 1998, Human gene therapy.

[33]  C. Mackay,et al.  The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. , 1998, The Journal of clinical investigation.

[34]  E. Edwards,et al.  Antilymphocyte induction therapy in cadaver renal transplantation: a retrospective, multicenter United Network for Organ Sharing Study. , 1997, Transplantation.

[35]  P. Halloran,et al.  Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. , 1997, Transplantation.

[36]  Simon A. Jones,et al.  Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes , 1996, The Journal of experimental medicine.

[37]  Strieter,et al.  Characterization of Chemokine Function in Animal Models of Diseases , 1996, Methods.

[38]  G. Berry,et al.  Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. , 1996, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[39]  D. Han,et al.  Analysis of interleukin-2 receptor expression in heart-lung transplanted mice. , 1994, Transplantation proceedings.

[40]  M. Suthanthiran,et al.  Regulation of new DNA synthesis in mammalian cells by cyclosporine. Demonstration of a transforming growth factor beta-dependent mechanism of inhibition of cell growth. , 1994, Transplantation.

[41]  C. Mackay,et al.  Homing of naive, memory and effector lymphocytes. , 1993, Current opinion in immunology.

[42]  D. Taub,et al.  Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells , 1993, The Journal of experimental medicine.

[43]  R. Strieter,et al.  The bimodal expression of tumor necrosis factor-alpha in association with rat lung reimplantation and allograft rejection. , 1993, Journal of immunology.

[44]  R. Strieter,et al.  Lung allograft rejection: role of tumor necrosis factor-alpha and interleukin-6. , 1993, Chest.

[45]  R. Strieter,et al.  Expression of interleukin-6 in association with rat lung reimplantation and allograft rejection. , 1993, The American review of respiratory disease.

[46]  N. Sigal,et al.  Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. , 1992, Annual review of immunology.

[47]  M. Burdick,et al.  The detection of a novel neutrophil-activating peptide (ENA-78) using a sensitive ELISA. , 1992, Immunological investigations.

[48]  M. Suthanthiran,et al.  Differential regulation of transforming growth factor beta and interleukin 2 genes in human T cells: demonstration by usage of novel competitor DNA constructs in the quantitative polymerase chain reaction , 1991, The Journal of experimental medicine.

[49]  A. Petersen,et al.  Diagnosis of rejection in rat lung allografts by bronchoalveolar lavage. , 1987, Transplantation proceedings.

[50]  E. Robin,et al.  Lung immunogenicity, rejection, and obliterative bronchiolitis. , 1987, Chest.

[51]  P. Nieuwenhuis,et al.  LUNG ALLOGRAFT REJECTION IN THE RAT: I. ACCELERATED REJECTION CAUSED BY GRAFT LYMPHOCYTES , 1985, Transplantation.

[52]  J. Crapo,et al.  Reimplantation response in isografted rat lungs. Analysis of causal factors. , 1984, The Journal of thoracic and cardiovascular surgery.

[53]  J. Prop Lung allograft rejection in the rat , 1984 .

[54]  C. Wildevuur,et al.  Lung transplantation in the rat: I. Technique and survival. , 1982, The Annals of thoracic surgery.

[55]  J. C. Norman,et al.  Lung transplantation in the rat. , 1971, Transplantation proceedings.